Piper Jaffray analyst Christopher Raymond remains a buyer of Deciphera Pharmaceuticals ahead of a “key” update for lead compound DCC2618 at this year’s European Society for Medical Oncology meeting. The analyst likes the near-term setup for the shares and keeps an Overweight rating on the name with a $50 price target. He thinks DCC2618’s “strong and competitive safety/efficacy profile” will “continue to hold up” at ESMO. Further, Raymond sees additional catalysts for Deciphera shares in 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.